泽布替尼联合年龄调整的苯达莫司汀和利妥昔单抗后续泽布替尼维持治疗在老年套细胞淋巴瘤患者中的疗效和安全性：一项回顾性分析

We retrospectively evaluated the efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance in 23 elderly patients with mantle cell lymphoma (MCL). Patients received six induction cycles of this regimen, followed by zanubrutinib maintenance for 2 years. After induction, the complete response rate was 73. 9% and the overall response rate was 91. 3%. The 24-month progression-free survival rate was 75.

4% and the overall survival rate was 90. 7%. Undetectable minimal residual disease (uMRD) was achieved in 88% of patients after induction and increased to 94% during maintenance. CD4 + T cell and NK cell counts declined to nadir post-induction but recovered by 12 months. Zanubrutinib combined with age-adapted bendamustine and rituximab, followed by zanubrutinib maintenance, is an active and feasible regimen for elderly patients with MCL, offering a potential treatment option in clinical practice.